報價延遲最少15分鐘:2026/03/10 01:46 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
146.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
6.78/9.35
|
|
企業價值
200.81B
|
| 資產負債 |
|
每股賬面淨值
18.29
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
29.44B
|
|
每股收益
22.06
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
